Verastem Oncology Eyes Self-Sustaining Growth in 2026 Amid Strong Revenue Launch and Expanding Pipeline
Market Chameleon (Wed, 4-Feb 10:41 AM)
Verastem Oncology Eyes Sustainable Growth with Strong AVMAPKI FAKZYNJA Launch and $234 Million Cash Buffer
Market Chameleon (Wed, 4-Feb 9:43 AM)
Verastem Oncology Shifts Focus After RAMP 203 Trial: Strategic Pivot Highlights Promise of Next-Gen KRAS G12D Inhibitor
Market Chameleon (Tue, 30-Dec 8:59 AM)
